Galactosyltransferase II in Detection of Pancreatic Cancer

Randall D. Cebul, Richard W. Sattin, Daniel K. Podolsky, Kurt J. Isselbacher

Research output: Contribution to journalLetter

Abstract

To the Editor: Podolsky et al. (May 28 issue),1 in evaluating test batteries that include galactosyltransferase isoenzyme II (GT-II) with one of the other recommended tests, have not specifically considered previously described principles of parallel-test use. When two tests used in parallel are being considered, the criterion for a positive battery may be either that both tests' results must be abnormal or that either test's results may be abnormal. The first criterion improves the battery's aggregate specificity but sacrifices its sensitivity, whereas the more liberal second criterion enhances sensitivity at the expense of specificity.2 , 3 The authors chose the “either test.

Original languageEnglish (US)
Pages (from-to)766-767
Number of pages2
JournalNew England Journal of Medicine
Volume305
Issue number13
DOIs
StatePublished - Sep 24 1981

Fingerprint

Pancreatic Neoplasms
Isoenzymes
galactosylxylosylprotein 3-beta-galactosyltransferase

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cebul, R. D., Sattin, R. W., Podolsky, D. K., & Isselbacher, K. J. (1981). Galactosyltransferase II in Detection of Pancreatic Cancer. New England Journal of Medicine, 305(13), 766-767. https://doi.org/10.1056/NEJM198109243051317

Galactosyltransferase II in Detection of Pancreatic Cancer. / Cebul, Randall D.; Sattin, Richard W.; Podolsky, Daniel K.; Isselbacher, Kurt J.

In: New England Journal of Medicine, Vol. 305, No. 13, 24.09.1981, p. 766-767.

Research output: Contribution to journalLetter

Cebul, RD, Sattin, RW, Podolsky, DK & Isselbacher, KJ 1981, 'Galactosyltransferase II in Detection of Pancreatic Cancer', New England Journal of Medicine, vol. 305, no. 13, pp. 766-767. https://doi.org/10.1056/NEJM198109243051317
Cebul, Randall D. ; Sattin, Richard W. ; Podolsky, Daniel K. ; Isselbacher, Kurt J. / Galactosyltransferase II in Detection of Pancreatic Cancer. In: New England Journal of Medicine. 1981 ; Vol. 305, No. 13. pp. 766-767.
@article{765bb15a93a44604922927f8d52db2f0,
title = "Galactosyltransferase II in Detection of Pancreatic Cancer",
abstract = "To the Editor: Podolsky et al. (May 28 issue),1 in evaluating test batteries that include galactosyltransferase isoenzyme II (GT-II) with one of the other recommended tests, have not specifically considered previously described principles of parallel-test use. When two tests used in parallel are being considered, the criterion for a positive battery may be either that both tests' results must be abnormal or that either test's results may be abnormal. The first criterion improves the battery's aggregate specificity but sacrifices its sensitivity, whereas the more liberal second criterion enhances sensitivity at the expense of specificity.2 , 3 The authors chose the “either test.",
author = "Cebul, {Randall D.} and Sattin, {Richard W.} and Podolsky, {Daniel K.} and Isselbacher, {Kurt J.}",
year = "1981",
month = "9",
day = "24",
doi = "10.1056/NEJM198109243051317",
language = "English (US)",
volume = "305",
pages = "766--767",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "13",

}

TY - JOUR

T1 - Galactosyltransferase II in Detection of Pancreatic Cancer

AU - Cebul, Randall D.

AU - Sattin, Richard W.

AU - Podolsky, Daniel K.

AU - Isselbacher, Kurt J.

PY - 1981/9/24

Y1 - 1981/9/24

N2 - To the Editor: Podolsky et al. (May 28 issue),1 in evaluating test batteries that include galactosyltransferase isoenzyme II (GT-II) with one of the other recommended tests, have not specifically considered previously described principles of parallel-test use. When two tests used in parallel are being considered, the criterion for a positive battery may be either that both tests' results must be abnormal or that either test's results may be abnormal. The first criterion improves the battery's aggregate specificity but sacrifices its sensitivity, whereas the more liberal second criterion enhances sensitivity at the expense of specificity.2 , 3 The authors chose the “either test.

AB - To the Editor: Podolsky et al. (May 28 issue),1 in evaluating test batteries that include galactosyltransferase isoenzyme II (GT-II) with one of the other recommended tests, have not specifically considered previously described principles of parallel-test use. When two tests used in parallel are being considered, the criterion for a positive battery may be either that both tests' results must be abnormal or that either test's results may be abnormal. The first criterion improves the battery's aggregate specificity but sacrifices its sensitivity, whereas the more liberal second criterion enhances sensitivity at the expense of specificity.2 , 3 The authors chose the “either test.

UR - http://www.scopus.com/inward/record.url?scp=0019887503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019887503&partnerID=8YFLogxK

U2 - 10.1056/NEJM198109243051317

DO - 10.1056/NEJM198109243051317

M3 - Letter

C2 - 6790994

AN - SCOPUS:0019887503

VL - 305

SP - 766

EP - 767

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 13

ER -